# SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

> **NCT01261312** · PHASE1,PHASE2 · COMPLETED · sponsor: **Astex Pharmaceuticals, Inc.** · enrollment: 414 (actual)

## Conditions studied

- MDS
- CMML
- AML

## Interventions

- **DRUG:** Guadecitabine

## Key facts

- **NCT ID:** NCT01261312
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-04
- **Primary completion:** 2016-07-22
- **Final completion:** 2016-07-22
- **Target enrollment:** 414 (ACTUAL)
- **Last updated:** 2025-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01261312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01261312, "SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01261312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*